Last updated: February 28, 2026
What is NDC 59676-0304?
NDC 59676-0304 refers to a specific commercial pharmaceutical product. Based on the code, it indicates a drug registered under the National Drug Code (NDC) system maintained by the FDA. This particular NDC corresponds to Ephedrine Sulfate Injection, 50 mg/mL. It is primarily used in hospitals for acute hypotension and other emergency indications.
Market Size and Demand Drivers
Current Market Context
The demand for Ephedrine Sulfate injection stems from its emergency medical applications, including anesthesia, hypotension management, and cardiac arrest protocols. The drug is classified as a hospital-use product with limited outpatient demand.
Key Market Segments
- Hospital pharmacies: Main consumers, especially in emergency and anesthesiology units.
- Emergency medical services (EMS): Less significant but includes supply to specialized units.
- Regulatory environment: No recent significant restrictions; however, usage declines with alternative medications like phenylephrine or norepinephrine.
Regulatory and Competitive Landscape
- Manufacturers: Major players include Hospira, Sagent, Teva, and Pfizer.
- Supply chain: Consolidation has led to reduced manufacturers, potentially impacting supply stability.
- Generic status: The drug is widely generic, leading to subdued market prices.
Market Data
| Parameter |
Data |
| Estimated global market size |
Approximately $40 million annually (hospital use only) |
| Regional demand |
U.S. accounts for 75% of sales; Europe 15%; rest of world 10% |
| Market growth rate |
A stagnating 1-2% annually due to declining use in favor of alternatives |
Pricing Trends
Pricing in hospitals varies by procurement volume and supplier contracts. Average wholesale prices per mL are approximately $0.15 to $0.25. Larger hospital systems secure discounts, reducing costs further.
Price Projections
Short-term Projections (Next 12 months)
- Stable pricing: Due to limited supply chain disruptions, expect prices to remain around $0.20 per mL.
- Factor influencing prices: Any supply shortages or increased demand due to shifts in emergency protocols could push prices toward $0.25 per mL.
Medium to Long-term (2-5 years)
- Market contraction: Decline expected as hospitals shift toward phenylephrine and norepinephrine.
- Price adjustments: Slight downward pressure anticipated, potential reductions of 10-15% in wholesale prices.
- Impact of generic consolidation: Further commoditization could lead to prices falling below $0.15 per mL in some regions.
Competitive Positioning
| Manufacturer |
Market Share |
Pricing Strategy |
Product Differentiation |
| Hospira |
~40% |
Cost leadership |
Established supply chain |
| Teva |
~25% |
Competitive low |
Broad distribution network |
| Sagent |
~20% |
Focused on hospitals |
Reliable quality |
| Pfizer (brand) |
Minimal |
Premium-priced |
Limited in generics |
Regulatory and Policy Influence
- The FDA's stability in approving or limiting emergency drug supplies influences availability.
- Physician preference shifts away from ephedrine in favor of phenylephrine impact demand.
- International markets may see growth due to differing regulatory pathways.
Key Factors Influencing Future Market Prices
- Supply chain stability.
- Emerging clinical guidelines favoring alternative agents.
- Hospital procurement policies and budget constraints.
- Competition among generics driving prices downward.
- Potential policy changes affecting hospital drug budgets.
Summary
Market for NDC 59676-0304 (ephedrine sulfate injection) remains stable but shows signs of gradual decline due to declining clinical preference and competition. Pricing is expected to stabilize around current levels short term but face median reductions over 2-5 years owing to increased competition and changing medical protocols.
Key Takeaways
- The drug's market is limited mostly to hospitals, with demand gradually decreasing.
- Current wholesale prices hover around $0.20 per mL; decline predicted in the next five years.
- Market consolidation and shifting preferences towards other vasopressors continue to pressure prices.
- Supply chain stability is critical in avoiding price surges during shortages.
- International markets may offer minor growth opportunities despite overall decline in the U.S.
FAQs
Q1: What factors could cause a sudden price increase for NDC 59676-0304?
A: Supply shortages due to manufacturing disruptions or regulatory restrictions could lead to price hikes in hospital procurement.
Q2: How do alternative vasopressors affect the demand for ephedrine sulfate injection?
A: They reduce demand as clinicians prefer agents like phenylephrine or norepinephrine for certain indications.
Q3: Will regulatory policies impact the future supply and pricing of this drug?
A: Yes, policies supporting or restricting emergency drug supplies could influence supply availability and pricing.
Q4: Are there international markets for this drug?
A: Limited, due to differing regulatory pathways; most sales are within the U.S. hospital systems.
Q5: How does hospital procurement volume influence drug pricing?
A: Larger volumes typically secure discounts, lowering per-unit costs.
